Products
Dibenzepine was still commercially available as extended-release film-coated tablets (Noveril TR, Novartis, formerly Wander). It was approved in many countries in 1968 and withdrawn from the market in 2016.
Structure and properties
Dibenzepine (C18H21N3O, Mr = 295.4 g/mol) is present in drugs as dibenzepine hydrochloride. It belongs to the dibenzepine group.
Effects
Dibenzepine (ATC N06AA08) has antidepressant and anticholinergic properties. The effects are due to inhibition of reuptake of norepinephrine into presynaptic neurons. Dibenzepine additionally binds to histamine H1 receptors in the brain and to cholinergic receptors.
Indications
For the relief of depression symptoms in adults.
Dosage
According to the professional information leaflet. Tablets are taken once or twice daily.
Contraindications
- Hypersensitivity
- Narrow-angle glaucoma
- Myocardial infarction
- Combination with MAO inhibitors
For complete precautions, see the drug label.
Interactions
Dibenzepine has a high potential for interaction.
Adverse effects
Possible adverse effects include:
